Enpowering Progression Risk of Cerebral Amyloid Angiopathy

Last updated: March 25, 2026
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Overall Status: Completed

Phase

N/A

Condition

Alzheimer's Disease

Amyloidosis

Treatment

N/A

Clinical Study ID

NCT06960538
PRIORITY
  • Ages > 18
  • All Genders

Study Summary

Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, and other clinical manifestations. Despite recent advances in diagnosis and understanding, many pathogenic, prognostic, and therapeutic aspects remain unclear.

Study Objective:

PRIORITY is a prospective observational study aimed at identifying clinical, neuroradiological, and biochemical biomarkers that could improve early diagnosis, risk stratification, and the identification of personalized therapeutic targets for CAA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • patients of either sex over 18 years of age;

  • patients with possible and probable symptomatic or asymptomatic CAA with or withouthistological demonstration (modified Boston criteria);

  • patients who have had at least one brain MRI.

Exclusion

Exclusion Criteria:

  • patients who have contraindications to undergoing brain MRI (e.g., pacemaker,incompatible mechanical valves, claustrophobia);

  • patients who have contraindications to or refuse to undergo lumbar puncture;

  • patients who are unable to provide informed consent for the study due to aphasic orcognitive impairment;

  • patients who are pregnant or breastfeeding.

Study Design

Total Participants: 200
Study Start date:
November 01, 2021
Estimated Completion Date:
September 30, 2025

Study Description

PRIORITY is a prospective, single-center observational study conducted at the Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan. It will consecutively enroll patients over 18 years of age with possible or probable cerebral amyloid angiopathy (CAA), symptomatic or asymptomatic, with or without histological confirmation. Diagnosis will follow the updated Boston criteria 2.0, and a brain MRI is mandatory for inclusion.

The study duration is 36 months, with clinical and neuroimaging assessments at baseline (T0), 12 months (T1), and 24 months (T2). CSF analysis will be performed at T0; plasma biomarkers (via ELISA and SIMOA) will be assessed at all time points. Lipid profiles will be analyzed using mass spectrometry with both untargeted and targeted lipidomic approaches (e.g., sphingolipidomics).

The comprehensive clinical and biological dataset will be used to develop a machine learning-based predictive model to support diagnostic, prognostic, and therapeutic decision-making in CAAThe study duration is 36 months, with clinical and neuroimaging assessments at baseline (T0), 12 months (T1), and 24 months (T2). CSF analysis will be performed at T0; plasma biomarkers (via ELISA and SIMOA) will be assessed at all time points. Lipid profiles will be analyzed using mass spectrometry with both untargeted and targeted lipidomic approaches (e.g., sphingolipidomics).

Connect with a study center

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan,
    Italy

    Site Not Available

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milano,
    Italy

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.